DeepMed Research

Tadalafil

Generic Name: Tadalafil

Brand Names: Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₁₉N_₃O_₄

CAS Number: 171596-29-5

Unique Ingredient Identifier: 742SXX0ICT

Background: Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.

Indication: Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.

Associated Conditions: Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)

Clinical Trials

Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB

Phase 4

Conditions: Overactive Bladder
Benign Prostatic Hyperplasia

Interventions: Drug: Tadalafil 5mg
Drug: Tamsulosin Hcl 0.4 mg
Drug: solifenacin 10 mg

First Posted Date: 2022-08-10

Last Posted Date: 2022-08-10

Lead Sponsor: Mansoura University

Target Recruit Count: 60

Registration Number: NCT05494567

Locations: 🇪🇬
Urology and Nephrology center, Mansoura, Egypt

Investigational and Comparative Study in the Management of Diabetic Nephropathy

Phase 3

Completed

Conditions: Diabetic Nephropathy Type 2

Interventions: Drug: Tadalafil 20Mg Oral Tablet
Drug: Pentoxifylline 400 MG Oral Tablet

First Posted Date: 2022-08-04

Last Posted Date: 2024-05-14

Lead Sponsor: Tanta University

Target Recruit Count: 90

Registration Number: NCT05487755

Locations: 🇪🇬
Faculty of pharmacy, Tanta, Egypt

Comparing The Effect of Tadalafil 5 mg/Day to Sildenafil 25 mg/Day on Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios in Erectile Dysfunction Patients; and Comparison of Clinical Response

Early Phase 1

Conditions: Erectile Dysfunction and Neutrophil Lymphocyte Ratio

Interventions: Drug: Tadalafil 5mg/sildenafil 25 mg

First Posted Date: 2022-07-20

Last Posted Date: 2022-07-20

Lead Sponsor: Assiut University

Target Recruit Count: 74

Registration Number: NCT05466695

Locations: 🇪🇬
Assiut University, Assiut, Egypt

Use of a Phosphodiesterase Type 5 Inhibitor to Improve Anabolic Resistance in Older Adults

Withdrawn

Conditions: Sarcopenia

Interventions: Drug: Tadalafil 5mg

First Posted Date: 2022-07-14

Last Posted Date: 2024-11-04

Lead Sponsor: University of Arkansas

Registration Number: NCT05458232

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction

Phase 4

Completed

Conditions: Erectile Dysfunction
Erectile Dysfunction With Diabetes Mellitus

Interventions: Drug: Tadalafil 5mg

First Posted Date: 2022-07-06

Last Posted Date: 2022-07-06

Lead Sponsor: Aswan University

Target Recruit Count: 60

Registration Number: NCT05446493

Locations: 🇪🇬
Aswan university, Aswan, Egypt

Efficiency of Tadalafil for Management of Female Sexual Dysfunction

Phase 2

Conditions: Sexual Dysfunction

Interventions: Drug: Tadalafil 5mg
Drug: Placebo

First Posted Date: 2022-03-04

Last Posted Date: 2022-03-04

Lead Sponsor: Kasr El Aini Hospital

Target Recruit Count: 24

Registration Number: NCT05266651

Locations: 🇪🇬
Kasr Elainy, Cairo, Egypt

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Macitentan 10 mg
Drug: Tadalafil 20 mg
Drug: Macitentan 10 mg/Tadalafil 20mg FDC

First Posted Date: 2022-02-11

Last Posted Date: 2025-03-30

Lead Sponsor: Actelion

Target Recruit Count: 40

Registration Number: NCT05236231

Locations: 🇺🇸
PRAHS, Salt Lake City, Utah, United States

Study of Tadalafil Vs. Placebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Physiology

Phase 3

Recruiting

Conditions: Fontan Palliation

Interventions: Drug: Placebo
Drug: Tadalafil

First Posted Date: 2022-01-25

Last Posted Date: 2024-11-11

Lead Sponsor: Mayo Clinic

Target Recruit Count: 80

Registration Number: NCT05206955

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Shock Wave vs. On-demand Tadalafil for Erectile Dysfunction

Not Applicable

Conditions: Erectile Dysfunction

Interventions: Device: LI-ESWT
Drug: Tadalafil 20Mg Oral Tablet

First Posted Date: 2022-01-20

Last Posted Date: 2022-01-20

Lead Sponsor: Menoufia University

Target Recruit Count: 50

Registration Number: NCT05199727

Locations: 🇪🇬
Menoufia University, Cairo, Egypt

Tadalafil as Adjuvant Therapy for DMD

Phase 2

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Tadalafil

First Posted Date: 2022-01-19

Last Posted Date: 2025-02-27

Lead Sponsor: University of Florida

Target Recruit Count: 25

Registration Number: NCT05195775

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy